Chance Pharma Acquires China Rights to Inhaled PAH Therapy
March 18, 2021 at 06:20 AM EDT
Hangzhou Chance Pharma signed a deal with Aerami Therapeutics to acquire greater China rights for a drug device combination product aimed at Pulmonary Arterial Hypertension. Aerami is a North Carolina clinical stage biopharma that develops inhaled therapies for severe respiratory and chronic diseases. AER-901 combines a patented inhalation device with imatinib, a tyrosine kinase inhibitor specific for PDGF-Rs, c-ΚΙΤ and BCR-ABL. Chance is a clinical-stage biotech focused on inhalation therapies. Financial details were not disclosed. More details.... Share this with colleagues: // //
